Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MetaStat Inc (EM) MTST

Healthcare Biotechnology
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of... see more

Current News (EXPM:MTST)

MetaStat Voluntarily Withdraws Listing on the OTCQB and Files Form 15 to Suspend its Reporting Obligations

Business Wire July 16, 2018

MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer

Business Wire June 21, 2018

MetaStat Announces Positive Topline Data Showing Over 50% Reduction in Cancer Metastasis from Preclinical Studies Evaluating Inhibition of the MAPKAPK2 Kinase Pathway

Business Wire February 28, 2018

MetaStat Announces Upcoming Investor and Pharmaceutical Industry Partnering Conference Presentations

Business Wire September 25, 2017

MetaStat Welcomes Renato T. Skerlj, Ph.D., Accomplished Drug Developer to Its Scientific and Clinical Advisory Board

Business Wire August 3, 2017

Study Demonstrates Paclitaxel Treatment Promotes Breast Cancer Dissemination and Metastasis in a Mena-dependent Manner

Business Wire July 19, 2017

MetaStat Closes First Round of a $7 Million Private Placement

Business Wire June 27, 2017

MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation

Business Wire June 19, 2017

MetaStat Expands Therapeutic and Companion Diagnostic Intellectual Property Portfolio

Business Wire May 23, 2017
View More News ››

Opinion & Analysis (EXPM:MTST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:MTST)

Be the first to post on this bullboard.

Vesalius Longevity Labs

Vesalius Longevity Labs

View More »

Podcasts